Polypharmacy for Schizophrenia

Current Opinion in Psychiatry - United States
doi 10.1097/yco.0b013e32835d9efb
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Polypharmacy in Schizophrenia

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2020English

Antipsychotic Patterns of Use in Patients With Schizophrenia: Polypharmacy Versus Monotherapy

BMC Psychiatry
PsychiatryMental Health
2014English

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2017English

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

BMC Psychiatry
PsychiatryMental Health
2005English

PS1-37: Comparison of Antipsychotic Polypharmacy Trends Among Schizophrenia Patients Across Multiple Healthcare Systems

Clinical Medicine and Research
MedicineHome CareCommunity
2014English

Addressing Polypharmacy

Journal of Gerontological Nursing
GerontologyNursing
2019English

Pediatric Polypharmacy

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2008English

Frailty and Polypharmacy

Journal of Nutrition, Health and Aging
MedicineNutritionGerontologyGeriatricsDietetics
2015English

Multimorbidity, Guidelines and Polypharmacy

Clinical Therapeutics
Pharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy